Document is current
Any future updates will be listed below
-
Authors
Fudim, Marat
Khan, Muhammad Shahzeb
Linz, Dominik
Lindenfeld, JoAnn
MacRae, Calum
Kimmeskamp-Kirschbaum, Nina
Meyer, Michaela
Mondritzki, Thomas
Tinel, Hanna
Dinh, Wilfried
Mentz, Robert J.
-
Funding
Funding for this research was provided by:
Bayer
- License Information
-
More Information
Article History
Received: 27 July 2024
Accepted: 21 October 2024
First Online: 30 December 2024
Declarations
:
: Fudim was supported by Bayer. Muhammad Shahzeb Khan reports fees from Bayer. JoAnn Lindenfeld has received grant funding from AstraZeneca and consulting fees from Abbott, Alleviant, Axon, Astra Zeneca, Boston Scientific, CVRx, Medtronic, Merck, Edwards Lifesciences, Whiteswell, Vascular Dynamics, Cordio, VWave. Calum MacRae has received grant funding from the American Heart Association, Apple, AstraZeneca, Bayer, Biosymetrics, Dewpoint Therapeutics, DinaQor, Dr. Evidence, Foresite Labs, Janssen, Pfizer, Platform Life Sciences, Samsung, Verily, Quest Diagnostics and is a co-founder of Atman Health and Tanaist. Nina Kimmeskamp-Kirschbaum, Michaela Meyer, Thomas Mondritzki, and Hanna Tinel are employees of Bayer AG and may own stock in the company. Wilfried Dinh was a full-time employee of Bayer AG during the conduct of the trial and may own stock in the company. Robert J Mentz has received research support and/or honoraria from Novartis, Abbott, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Cytokinetics, Fast BioMedical, Gilead, Innolife, Eli Lilly, Medtronic, Medable, Merck, Novo Nordisk, Pharmacosmos, Relypsa, Respicardia, Roche, Sanofi, Vifor, Windtree Therapeutics, and Zoll. Dominik Linz has no disclosures to report.
